Regulation FD Disclosure

Kardigan, Inc. — Form 8-K Summary

Filing date: November 6, 2026. This is an event-driven report, not a periodic financial report. Kardigan’s common stock trades on Nasdaq under KARD.

Business context and key development

Kardigan announced completion of enrollment in its Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis. The trial’s primary endpoint, aortic valve calcium, will be assessed at week 48, alongside aortic valve area and measures of cardiac structure and function.

Financial information

The filing provides no revenue, earnings, cash flow, margin, debt, liquidity, or other financial metrics, and no comparable-period financial results.

Outlook, risks, and unusual items

  • The company said topline results are currently expected in the second half of 2026. The filing does not provide a more specific timing or results.
  • Kardigan planned an investor webcast from the American Heart Association Scientific Sessions for November 7, 2026, at 8:00 a.m. ET.
  • The filing describes no specific risks, contingencies, or financial guidance. The event announcement is furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act.

Important facts for investors to verify

  • Whether and when the week-48 endpoint assessment and topline results are reported.
  • The trial results, including the primary endpoint and measures of valve area and cardiac structure and function.
  • Any subsequent company disclosures that update the anticipated timing or provide additional trial details.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.